
    
      This is an extension study to evaluate the long-term safety, tolerability, and efficacy of
      two dose strengths of dalfampridine-ER twice daily tablets when administered for at least 12
      months to subjects with chronic post-ischemic stroke walking deficits who have completed the
      controlled, double-blind Study DALF-PS-1016.
    
  